How much profit has Immunitybio made this year?
Immunitybio has made -525.52 M USD this year.
Immunitybio Net Income 2024
Immunitybio Net Income
-525.52 M USD
Ticker
IBRX
ISIN
US45256X1037
WKN
A2QQ2E
In 2024, Immunitybio's profit amounted to -525.52 M USD, a -9.89% increase from the -583.2 M USD profit recorded in the previous year.
The Immunitybio Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2026e | - |
| 2025e | - |
| 2024e | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
| 2014 | - |
| 2013 | - |
Immunitybio Revenue, EBIT, Net Income US45256X1037 · A2QQ2E
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Immunitybio, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Immunitybio from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Immunitybio’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Immunitybio. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Immunitybio’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Immunitybio’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Immunitybio’s growth potential.
Immunitybio Revenue, Profit, and EBIT History
| Date | Immunitybio Revenue | Immunitybio EBIT | Immunitybio Net Income |
|---|---|---|---|
| 2026e | 531.65 M undefined | 5.08 M undefined | -109.34 M undefined |
| 2025e | 282.93 M undefined | -191.25 M undefined | -366.81 M undefined |
| 2024e | 72.99 M undefined | -338.43 M undefined | -525.52 M undefined |
| 2023 | 622,000 undefined | -361.36 M undefined | -583.2 M undefined |
| 2022 | 240,000 undefined | -350.62 M undefined | -416.57 M undefined |
| 2021 | 930,000 undefined | -330.28 M undefined | -346.79 M undefined |
| 2020 | 610,000 undefined | -210.22 M undefined | -221.85 M undefined |
| 2019 | 2.2 M undefined | -156.25 M undefined | -157.78 M undefined |
| 2018 | 50,000 undefined | -98.39 M undefined | -96.23 M undefined |
| 2017 | 50,000 undefined | -99.12 M undefined | -96.42 M undefined |
| 2016 | 40,000 undefined | -124.5 M undefined | -120.81 M undefined |
| 2015 | 240,000 undefined | -238.88 M undefined | -236.88 M undefined |
| 2014 | 640,000 undefined | -5.58 M undefined | -6.19 M undefined |
| 2013 | 600,000 undefined | -2.27 M undefined | -2.05 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2013 | 600,000 USD | -2.27 M USD | -2.05 M USD |
| 2014 | 640,000 USD | -5.58 M USD | -6.19 M USD |
| 2015 | 240,000 USD | -238.88 M USD | -236.88 M USD |
| 2016 | 40,000 USD | -124.5 M USD | -120.81 M USD |
| 2017 | 50,000 USD | -99.12 M USD | -96.42 M USD |
| 2018 | 50,000 USD | -98.39 M USD | -96.23 M USD |
| 2019 | 2.2 M USD | -156.25 M USD | -157.78 M USD |
| 2020 | 610,000 USD | -210.22 M USD | -221.85 M USD |
| 2021 | 930,000 USD | -330.28 M USD | -346.79 M USD |
| 2022 | 240,000 USD | -350.62 M USD | -416.57 M USD |
| 2023 | 622,000 USD | -361.36 M USD | -583.2 M USD |
| 2024e | 72.99 M USD | -338.43 M USD | -525.52 M USD |
| 2025e | 282.93 M USD | -191.25 M USD | -366.81 M USD |
| 2026e | 531.65 M USD | 5.08 M USD | -109.34 M USD |
Immunitybio stock margins US45256X1037 · A2QQ2E
The Immunitybio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Immunitybio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Immunitybio.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Immunitybio's sales revenue. A higher gross margin percentage indicates that the Immunitybio retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Immunitybio's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Immunitybio's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Immunitybio's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Immunitybio. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Immunitybio's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Immunitybio Margin History
| Immunitybio Gross margin | Immunitybio Profit margin | Immunitybio EBIT margin | Immunitybio Profit margin |
|---|---|---|---|
| 2026e | 0 % | 0.95 % | -20.57 % |
| 2025e | 0 % | -67.6 % | -129.65 % |
| 2024e | 0 % | -463.69 % | -720.03 % |
| 2023 | 0 % | -58,097.11 % | -93,761.41 % |
| 2022 | 0 % | -146,091.66 % | -173,570.84 % |
| 2021 | 0 % | -35,513.98 % | -37,289.25 % |
| 2020 | 0 % | -34,462.3 % | -36,368.85 % |
| 2019 | 0 % | -7,102.27 % | -7,171.82 % |
| 2018 | 0 % | -196,779.99 % | -192,460.01 % |
| 2017 | 0 % | -198,240 % | -192,839.99 % |
| 2016 | 0 % | -311,250 % | -302,025 % |
| 2015 | 0 % | -99,533.34 % | -98,700.01 % |
| 2014 | 0 % | -871.88 % | -967.19 % |
| 2013 | 0 % | -378.33 % | -341.67 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2013 | 0 % | -378.33 % | -341.67 % |
| 2014 | 0 % | -871.88 % | -967.19 % |
| 2015 | 0 % | -99,533.34 % | -98,700.01 % |
| 2016 | 0 % | -311,250 % | -302,025 % |
| 2017 | 0 % | -198,240 % | -192,839.99 % |
| 2018 | 0 % | -196,779.99 % | -192,460.01 % |
| 2019 | 0 % | -7,102.27 % | -7,171.82 % |
| 2020 | 0 % | -34,462.3 % | -36,368.85 % |
| 2021 | 0 % | -35,513.98 % | -37,289.25 % |
| 2022 | 0 % | -146,091.66 % | -173,570.84 % |
| 2023 | 0 % | -58,097.11 % | -93,761.41 % |
| 2024e | 0 % | -463.69 % | -720.03 % |
| 2025e | 0 % | -67.6 % | -129.65 % |
| 2026e | 0 % | 0.95 % | -20.57 % |
Immunitybio Aktienanalyse
What does Immunitybio do?
Translate this as near as possible to English. ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong. The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics. In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology. ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies. Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment. The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study. Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide. Immunitybio ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Immunitybio's Profit Margins
The profit margins of Immunitybio represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Immunitybio's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Immunitybio's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Immunitybio's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Immunitybio’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Immunitybio Stock
How has the profit developed compared to last year?
The profit has increased by -9.89% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Immunitybio publish its earnings?
Immunitybio publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Immunitybio?
The profits of Immunitybio are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Immunitybio?
You can learn more about the earnings of Immunitybio by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Immunitybio pay?
Over the past 12 months, Immunitybio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunitybio is expected to pay a dividend of 0 USD.
What is the dividend yield of Immunitybio?
The current dividend yield of Immunitybio is .
When does Immunitybio pay dividends?
Immunitybio pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immunitybio?
Immunitybio paid dividends every year for the past 0 years.
What is the dividend of Immunitybio?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immunitybio located?
Immunitybio is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immunitybio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immunitybio from 6/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/16/2024.
When did Immunitybio pay the last dividend?
The last dividend was paid out on 6/16/2024.
What was the dividend of Immunitybio in the year 2023?
In the year 2023, Immunitybio distributed 0 USD as dividends.
In which currency does Immunitybio pay out the dividend?
The dividends of Immunitybio are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immunitybio
Our stock analysis for Immunitybio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunitybio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
